Lin Gui Yiming Zhu Xiaomo Li Xiaohui He Tonghui Ma Yi Cai Shaoyan Liu
10.3389/fimmu.2023.1178682
Front Immunol
2023 Apr 14;14:1178682.
braf non-v600e nras anaplastic thyroid carcinoma (atc) case report combination immunotherapy and targeted therapy
CC BY
https://pubmed.ncbi.nlm.nih.gov/37122752/
Thyroid Carcinoma, Anaplastic / drug therapy Thyroid Carcinoma, Anaplastic / genetics Thyroid Carcinoma, Anaplastic / pathology Thyroid Neoplasms / drug therapy Thyroid Neoplasms / genetics
Thyroid Carcinoma, Anaplastic / drug therapy Thyroid Carcinoma, Anaplastic / genetics Thyroid Carcinoma, Anaplastic / pathology Thyroid Neoplasms / drug therapy Thyroid Neoplasms / genetics Case Reports GTP Phosphohydrolases / genetics Humans Membrane Proteins / genetics Mutation Programmed Cell Death 1 Receptor / genetics Proto-Oncogene Proteins B-raf / genetics trametinib dabrafenib Proto-Oncogene Proteins B-raf Programmed Cell Death 1 Receptor BRAF protein, human NRAS protein, human Membrane Proteins GTP Phosphohydrolases
PMC10140402
37122752
Case report: Complete response of an anaplastic thyroid carcinoma patient with NRAS Q61R/ BRAF D594N mutations to the triplet of dabrafenib, trametinib and PD-1 antibody
2023